贝伐单抗与结直肠癌肝转移患者术后伤口并发症

Bevacizumab and postoperative wound complications in patients with liver metastases of colorectal cancer.

作者信息

Utsumi Hirofumi, Honma Yoshitaka, Nagashima Kengo, Iwasa Satoru, Takashima Atsuo, Kato Ken, Hamaguchi Tetsuya, Yamada Yasuhide, Shimada Yasuhiro, Kishi Yoji, Nara Satoshi, Esaki Minoru, Shimada Kazuaki

机构信息

Gastrointestinal Medical Oncology Division, National Cancer Center Hospital, Tokyo, Japan.

Gastrointestinal Medical Oncology Division, National Cancer Center Hospital, Tokyo, Japan

出版信息

Anticancer Res. 2015 Apr;35(4):2255-61.

PMID:25862887

Abstract

AIM

The present study investigated whether bevacizumab (BV) is associated with postoperative wound complications (PWCs).

PATIENTS AND METHODS

We retrospectively analyzed patients undergoing surgery for liver metastases of colorectal cancer at our Institution. Patients were divided into 3 groups according to the preoperative treatment: che mo therapy with BV (group A), chemotherapy without BV (group B) and no chemotherapy (group C).

RESULTS

Between February 2003 and September 2012, 297 patients underwent 373 surgeries. Groups A, B and C consisted of 23, 62 and 288 patients, respectively. PWCs occurred in 29 patients (7.8%). In multivariate analysis, there were no differences in PWCs among the groups (C vs. B:P=0.739; C vs. A: P=0.110). Conversely, lower serum albumin levels (<3.5 g/dl vs. ≥ 3.5 g/dl: p=0.030) and synchronous colorectal resection (no vs. yes; p<0.001) remained significant risk factors of developing PWCs.

CONCLUSION

Chemotherapy with or without BV did not influence the risk of PWCs.

摘要

目的

本研究调查贝伐单抗（BV）是否与术后伤口并发症（PWC）相关。

患者与方法

我们回顾性分析了在本院接受结直肠癌肝转移手术的患者。根据术前治疗情况将患者分为3组：BV化疗组（A组）、非BV化疗组（B组）和未化疗组（C组）。

结果

2003年2月至2012年9月期间，297例患者接受了373次手术。A组、B组和C组分别有23例、62例和288例患者。29例患者（7.8%）发生了PWC。多因素分析显示，各组间PWC发生率无差异（C组与B组：P = 0.739；C组与A组：P = 0.110）。相反，较低的血清白蛋白水平（<3.5 g/dl与≥3.5 g/dl：p = 0.030）和同期结直肠切除术（否与是；p<0.001）仍然是发生PWC的显著危险因素。